Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data [Seeking Alpha]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Seeking Alpha
Summary Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expected in Q4 of 2024. Preliminary RECIST response data from 10 patients using the lunresertib + camonsertib combination for ovarian and endometrial cancer patients was 50%. The global ovarian cancer market is expected to reach $11.18 billion by 2029. Initial results from the phase 1/2 TRESR study, using camonsertib as a monotherapy treatment for patients with non-small cell lung cancer, are expected in 2025. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Image Source Repare Therapeutics Inc. NASDAQ: RPTX ) is gearing up to report results from its phase 1 MYTHIC trial, which is using lunresertib [RP-6306] in combination with camonsertib [RP-3500] for the treatment of patients with platinum-resistant ovarian a
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsBusiness Wire
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Repare Therapeutics' individualised anaemia management trial shows promise [Yahoo! Finance]Yahoo! Finance
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 11/7/24 - Form 424B5
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- RPTX's page on the SEC website